NASDAQ:INKT MiNK Therapeutics (INKT) Stock Forecast, Price & News $1.92 +0.10 (+5.49%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$1.82▼$1.9550-Day Range$0.89▼$2.2752-Week Range$0.85▼$4.32Volume46,383 shsAverage Volume83,116 shsMarket Capitalization$66.09 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MiNK Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside160.4% Upside$5.00 Price TargetShort InterestHealthy1.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$362,492 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.75) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector678th out of 981 stocksBiological Products, Except Diagnostic Industry107th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingMiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, MiNK Therapeutics has a forecasted upside of 160.4% from its current price of $1.92.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.93% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently increased by 70.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INKT. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 3 people have searched for INKT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows10 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have bought 281.57% more of their company's stock than they have sold. Specifically, they have bought $362,492.00 in company stock and sold $95,000.00 in company stock.Percentage Held by Insiders13.21% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.41% of the stock of MiNK Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($0.75) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MiNK Therapeutics (NASDAQ:INKT) StockMiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Read More Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INKT Stock News HeadlinesMay 23, 2023 | cbsnews.com"Off-the-shelf" cell therapy shows promise for cancers resistant to current treatments, including immunotherapiesMay 22, 2023 | finance.yahoo.comMiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International ConferenceJune 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 18, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for MiNK Therapeutics (INKT)May 18, 2023 | finance.yahoo.comMiNK's Novel FAP-CAR-iNKT Presented at ASGCTMay 16, 2023 | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) Rating Reiterated by B. RileyMay 16, 2023 | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) Given "Buy" Rating at B. RileyMay 15, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on MiNK Therapeutics (INKT)June 6, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 14, 2023 | americanbankingnews.comAgenus Inc Acquires 22,065 Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) StockMay 12, 2023 | msn.comRecap: MiNK Therapeutics Q1 EarningsMay 12, 2023 | msn.comThe Latest Analyst Ratings for MiNK TherapeuticsMay 12, 2023 | markets.businessinsider.comMiNK Therapeutics (INKT) Has a New Rating from H.C. WainwrightMay 12, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on MiNK Therapeutics (INKT)May 11, 2023 | finance.yahoo.comMiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial ResultsMay 9, 2023 | americanbankingnews.comMiNK Therapeutics (INKT) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2023 | americanbankingnews.comInsider Selling: MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Sells $95,000.00 in StockMay 8, 2023 | americanbankingnews.comInsider Buying: MiNK Therapeutics, Inc. (NASDAQ:INKT) Major Shareholder Acquires $95,190.00 in StockMay 8, 2023 | americanbankingnews.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Major Shareholder Buys $138,984.12 in StockMay 7, 2023 | americanbankingnews.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Director Purchases $95,000.00 in StockApril 27, 2023 | finance.yahoo.comMiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial ResultsApril 23, 2023 | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC WainwrightApril 21, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on MiNK Therapeutics (INKT)April 18, 2023 | finance.yahoo.comMiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual MeetingApril 16, 2023 | finance.yahoo.comWe're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn RateApril 4, 2023 | finance.yahoo.comMiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 30, 2023 | finance.yahoo.comAgenus Announces Dividend of 5 Million Shares of MiNK TherapeuticsSee More Headlines INKT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INKT Company Calendar Last Earnings3/21/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INKT CUSIPN/A CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.00 High Stock Price Forecast$0.00 Low Stock Price Forecast$10,000,000.00 Forecasted Upside/Downside+170.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-665.42% Return on Assets-109.70% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-185.00Miscellaneous Outstanding Shares34,420,000Free Float29,875,000Market Cap$63.68 million OptionableNot Optionable Beta-0.60 Key ExecutivesDr. Garo H. Armen Ph.D. (Age 69)Exec. Chairman Dr. Jennifer S. Buell Ph.D. (Age 47)Pres, CEO & Director Comp: $232.54kDr. Marcus Antonius van Dijk Ph.D. (Age 60)Chief Scientific Officer Ms. Christine M. Klaskin (Age 56)Treasurer Comp: $20.02kMr. Patrick N. Jordan M.B.A.VP of Bus. OperationsMs. Kimberly HaHead of Investor RelationsMs. Heather BoussiosGen. Counsel & Chief Compliance OfficerJoy Zhou Ph.D.VP & Head of CMCMore ExecutivesKey CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXDyadic InternationalNASDAQ:DYAITradeUP AcquisitionNASDAQ:UPTDTCR2 TherapeuticsNASDAQ:TCRRCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsiders & InstitutionsFirst Republic Investment Management Inc.Sold 20,100 shares on 5/12/2023Ownership: 0.094%Agenus IncBought 22,065 shares on 5/10/2023Total: $33,318.15 ($1.51/share)Agenus IncBought 100,200 shares on 5/5/2023Total: $95,190.00 ($0.95/share)Garo H ArmenSold 100,000 sharesTotal: $95,000.00 ($0.95/share)Agenus IncBought 128,689 shares on 5/3/2023Total: $138,984.12 ($1.08/share)View All Insider TransactionsView All Institutional Transactions INKT Stock - Frequently Asked Questions Should I buy or sell MiNK Therapeutics stock right now? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" INKT shares. View INKT analyst ratings or view top-rated stocks. What is MiNK Therapeutics' stock price forecast for 2023? 0 brokerages have issued 12 month price objectives for MiNK Therapeutics' shares. Their INKT share price forecasts range from $10,000,000.00 to $0.00. On average, they predict the company's share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for INKT or view top-rated stocks among Wall Street analysts. How have INKT shares performed in 2023? MiNK Therapeutics' stock was trading at $2.61 at the start of the year. Since then, INKT stock has decreased by 29.1% and is now trading at $1.85. View the best growth stocks for 2023 here. Are investors shorting MiNK Therapeutics? MiNK Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 180,500 shares, an increase of 70.4% from the April 30th total of 105,900 shares. Based on an average daily trading volume, of 120,600 shares, the short-interest ratio is currently 1.5 days. Approximately 1.9% of the company's shares are sold short. View MiNK Therapeutics' Short Interest. When is MiNK Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our INKT earnings forecast. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) released its quarterly earnings data on Tuesday, March, 21st. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.02. What ETFs hold MiNK Therapeutics' stock? ETFs with the largest weight of MiNK Therapeutics (NASDAQ:INKT) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did MiNK Therapeutics IPO? (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share. What is MiNK Therapeutics' stock symbol? MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT." Who are MiNK Therapeutics' major shareholders? MiNK Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include First Republic Investment Management Inc. (0.09%). Insiders that own company stock include Agenus Inc, Garo H Armen and Ulf Wiinberg. View institutional ownership trends. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MiNK Therapeutics' stock price today? One share of INKT stock can currently be purchased for approximately $1.85. How much money does MiNK Therapeutics make? MiNK Therapeutics (NASDAQ:INKT) has a market capitalization of $63.68 million. The company earns $-27,990,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How can I contact MiNK Therapeutics? The official website for the company is www.minktherapeutics.com. The company can be reached via phone at 212-994-8250 or via email at investor@minktherapeutics.com. This page (NASDAQ:INKT) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.